Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP III: Abatacept in primary Sjögren's syndrome
2014-000417-31Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary Sjögren's syndrome comparing Abatacept weekly SC with Placebo weekly SC (2 arms). Primary endpoint: ESSDAI at 24 weeks. Started Mar 2014; status: completed.
02
Drugs
abatacept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2014-000417-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000417-31.